Market Overview

UPDATE: BMO Capital Downgrades Pfizer

Related PFE
Pfizer Inc. Stock Fails To Break Out: Is It Headed Back Down?
#PreMarket Primer: Monday, September 29: Protesters Vow To Continue Fighting For Democracy In Hong Kong
Martoma Hit with Nine-Year Prison Sentence (Fox Business)

In a report released Monday, BMO Capital analyst Alex Arfaei downgraded Pfizer (NYSE: PFE) from Outperform to Market Perform while reducing its price target from $34 to $31.

Analysts at BMO stated Pfizer has "limited growth prospects." Pfizer's new drug releases do not outweigh its mature franchises heavily declining dividend; backpacks create some short-term support, but not enough for growth maintenance.

Latest Ratings for PFE

DateFirmActionFromTo
Aug 2014Deutsche BankInitiates Coverage onBuy
Jul 2014BMO CapitalDowngradesOutperformMarket Perform
Jul 2014JefferiesMaintainsBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Alex Arfaei BMO CapitalDowngrades Price Target Analyst Ratings

 

Related Articles (PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters